Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship

AK Ceranski, MJ Carreño-Gonzalez, AC Ehlers… - Molecular cancer, 2023 - Springer
Hypoxia develops during the growth of solid tumors and influences tumoral activity in
multiple ways. Low oxygen tension is also present in the bone microenvironment where …

Involvement of neuronal factors in tumor angiogenesis and the shaping of the cancer microenvironment

S Shalabi, A Belayachi, B Larrivée - Frontiers in Immunology, 2024 - frontiersin.org
Emerging evidence suggests that nerves within the tumor microenvironment play a crucial
role in regulating angiogenesis. Neurotransmitters and neuropeptides released by nerves …

Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma

C Lu, A Mahajan, SH Hong, S Galli, S Zhu… - Nature …, 2022 - nature.com
Adverse prognosis in Ewing sarcoma (ES) is associated with the presence of metastases,
particularly in bone, tumor hypoxia and chromosomal instability (CIN). Yet, a mechanistic …

Neuropeptide Y peptide family and cancer: Antitumor therapeutic strategies

ML Sánchez, FD Rodríguez, R Coveñas - International Journal of …, 2023 - mdpi.com
Currently available data on the involvement of neuropeptide Y (NPY), peptide YY (PYY), and
pancreatic polypeptide (PP) and their receptors (YRs) in cancer are updated. The structure …

Identification of mithramycin analogues with improved targeting of the EWS-FLI1 transcription factor

CL Osgood, N Maloney, CG Kidd… - Clinical Cancer …, 2016 - AACR
Purpose: The goal of this study was to identify second-generation mithramycin analogues
that better target the EWS-FLI1 transcription factor for Ewing sarcoma. We previously …

Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread

D Sigorski, W Wesołowski, A Gruszecka… - Journal of Cancer …, 2023 - Springer
Abstract Purpose Neuropeptide Y (NPY) is a pleiotropic peptide, which is involved in many
biological mechanisms important in regulation of cell growth and survival. The aim of this …

DPPIV/CD26: a tumor suppressor or a marker of malignancy?

A Beckenkamp, S Davies, JB Willig, A Buffon - Tumor Biology, 2016 - Springer
Abstract Dipeptidyl peptidase IV (DPPIV/CD26) is a multifunctional protein with intrinsic
peptidase activity that inactivates or degrades some bioactive peptides. It is the main cellular …

[HTML][HTML] One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma

G Flores, PJ Grohar - Journal of bone oncology, 2021 - Elsevier
EWS/FLI is the defining mutation of Ewing sarcoma. This oncogene drives malignant
transformation and progression and occurs in a genetic background characterized by few …

Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology

J Tilan, J Kitlinska - Neuropeptides, 2016 - Elsevier
Neuropeptide Y (NPY) is a sympathetic neurotransmitter with pleiotropic actions, many of
which are highly relevant to tumor biology. Consequently, the peptide has been implicated …

Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease―Recent Insights Focusing on Angiogenesis and Neovascularization―

Y Lei, L Hu, G Yang, L Piao, M Jin, X Cheng - Circulation Journal, 2017 - jstage.jst.go.jp
Abstract Dipeptidyl peptidase IV (DPP-IV) is a complex enzyme that acts as a membrane-
anchored cell surface exopeptidase and transmits intracellular signals through a small …